| Kathie Robbins, CRNFA | |
|
Sheridan St, Waretown, NJ 08758-2301 | |
| (732) 600-8693 | |
| (609) 693-9388 |
| Full Name | Kathie Robbins |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Registered Nurse First Assistant |
| Location | Sheridan St, Waretown, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245309509 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WR0006X | Registered Nurse - Registered Nurse First Assistant | 26NO04889900 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kathie Robbins, CRNFA 84 Sheridan St, Waretown, NJ 08758-2301 Ph: (732) 600-8693 | Kathie Robbins, CRNFA Sheridan St, Waretown, NJ 08758-2301 Ph: (732) 600-8693 |
News Archive
SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced it has signed a Memorandum of Understanding (MOU) with SporTracker Ltd, a private Israeli company that specializes in the integration of heart-rate monitoring with consumer audio and leisure devices.
Men with a family history of prostate cancer and African-American men are particularly susceptible to the disease, with a twofold to sevenfold increased risk. Assessing risk in these populations has been difficult.
Women in midlife underreport the number of hot flashes that they experience by more than 40 percent, and these hot flashes are linked to poor verbal memory, according to a study by researchers at the University of Illinois at Chicago.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Pfizer Inc. and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp). There is currently an unmet need for new treatment options and the World Health Organization (WHO) estimates that some 30 million pregnant women are at risk for malaria in endemic areas in Africa each year.
› Verified 5 days ago